| 0.4572 -0.022 (-4.63%) | 02-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.14  |
1-year : | 1.52 |
| Resists | First : | 0.98 |
Second : | 1.3 |
| Pivot price | 0.58 |
|||
| Supports | First : | 0.44 |
Second : | 0.37 |
| MAs | MA(5) : | 0.49 |
MA(20) : | 0.61 |
| MA(100) : | 10.17 |
MA(250) : | 186.13 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 0.8 |
D(3) : | 2.3 |
| RSI | RSI(14): 26.1 |
|||
| 52-week | High : | 1977.5 | Low : | 0.44 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ADTX ] has closed above bottom band by 10.5%. Bollinger Bands are 98.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 71 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.52 - 0.53 | 0.53 - 0.53 |
| Low: | 0.47 - 0.48 | 0.48 - 0.48 |
| Close: | 0.47 - 0.48 | 0.48 - 0.48 |
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Mon, 23 Feb 2026
ADTX Fundamental Analysis | ADITXT INC (NASDAQ:ADTX) - ChartMill
Thu, 29 Jan 2026
Aditxt Receives Nasdaq Extension to Regain Listing Compliance - The Globe and Mail
Wed, 21 Jan 2026
Aditxt To Hold Virtual Special Meeting Of Shareholders This Month - Nasdaq
Wed, 17 Dec 2025
Aditxt (ADTX) Stock Surges After Proxy Filing Sets Up Reverse Split Vote and “bitXbio” Name Change — What to Know on Dec. 17, 2025 - TechStock²
Fri, 28 Nov 2025
Aditxt’s Bold Strategy Spurs Market Buzz - StocksToTrade
Tue, 18 Nov 2025
Aditxt (Nasdaq: ADTX) outlines bitXbio plan, Pearsanta 2026 IPO and Evofem stake - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 510200 (%) |
| Held by Institutions | 8.8 (%) |
| Shares Short | 121 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.018e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -419 % |
| Return on Assets (ttm) | 870.3 % |
| Return on Equity (ttm) | -61.8 % |
| Qtrly Rev. Growth | 5950 % |
| Gross Profit (p.s.) | -59.01 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -44721.9 |
| Qtrly Earnings Growth | -829.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 49980 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|